Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

RyMed Tech. Wins Patent Infringement Case Against ICU Medical - Quick Facts

RELATED NEWS
Trade ICUI now with 

A federal jury has found in favor of RyMed Technologies and against ICU Medical (ICUI: Quote) in a closely-watched patent infringement case, and ruled that RyMed's InVision-Plus with Neutral AdvantageTM technology products do not infringe on a patent held by ICU Medical.

Dana Wm. Ryan, President, CEO and Chairman of the Board of RyMed said the unanimous ruling by an eight-person jury means that ICU Medical can no longer make any claim that RyMed's products literally infringe on an in-force ICU Medical patent.

Commention on the jury's decision, Ryan continued, " It reinforces our ability to continue providing all of RyMed's innovative technology to the market. In addition to providing a significant boost to our future business prospects, it also affirms our ongoing efforts to bring clinicians and patients the very best in IV catheter safety technology."

The jury decision was announced Wednesday, May 9th in a case heard before Judge Leonard P. Stark, in the United States District Court for the District of Delaware.

Click here to receive FREE breaking news email alerts for ICU Medical and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Toyota Motor Corp. (TM, TYT.L) Thursday announced 1.1 percent decline in worldwide production for October, as there was a sharp decline in production of passenger cars in Japan. Production outside Japan improved 2.3 percent. In a separate announcement, the Japanese automaker said it will recall more... Computer and printer maker Hewlett-Packard Co. said Tuesday after the markets closed that its fourth quarter profit fell 6% from last year, as revenue declined 2%. The company's quarterly earnings per share, excluding items, came in line with analysts' expectations, but its quarterly revenue fell short of analysts' forecast. This organic and natural products company has experienced strong compounded annual growth over the last four fiscal years with its net sales growing 25% and adjusted income from continuing operations over 30%.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.